Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
about
Valproic acid pathwayImpact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen.Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.Valproic acid pathway: pharmacokinetics and pharmacodynamics.Antiepileptic drug interactions - principles and clinical implications.Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivoIn vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.Soybean greatly reduces valproic acid plasma concentrations: a food-drug interaction studyGenetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.Clinically relevant drug interactions in anxiety disorders.Methodologies used to identify and characterize interactions among antiepileptic drugs.Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.Pharmacokinetic Interactions between Valproic Acid and Lorazepam (PIVOtAL Study): A Review of Site-Specific Practices.Pharmacogenomics and histone deacetylase inhibitors.Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.Influence of the UGT2B7 -161C>T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients.Association of genetic variants in six candidate genes with valproic acid therapy optimization.Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation.
P2860
Q30225432-6E7B25C8-77BD-4935-BB1E-2A22B65821E3Q31111176-BA3D4C18-5B34-44FF-9077-4CC015B3CFAFQ33664128-D23878CB-8042-4200-89BF-5E133D5CEDC7Q33804773-31E7D41A-5852-403D-89AF-A9F4F817621BQ34273354-377E68D1-BAFF-4B8B-83C8-BC43AE59F419Q34327652-01E79777-563A-4CA9-BA19-10E7FDB2B8EBQ34402188-0504CCE2-D9E4-4173-99D1-7878DAE33301Q36808178-B33053DA-F12A-465C-B5BE-7F2168BA1869Q37107040-0DEF7477-F2D3-4673-BC3B-45AC60715AC3Q37415778-BEE0CC06-11B9-4610-B986-3BD24A795811Q37631643-BDB96375-C9E8-4C09-B0A4-2D077412EE09Q37775981-583673B6-9746-4228-A9DF-D9A12BE0D202Q37981951-F7EE4B25-9E93-4A91-BF38-0BA138F34F03Q38018676-A6545B32-EF0D-40CC-A92E-F47962AB9E1CQ38030052-0EC6844F-6834-459F-9DBA-F4D8D2FA726EQ38692133-13262C78-710C-44C8-8524-62CE339348FFQ38987332-2593F7E1-0D81-469D-BD10-05F90514A616Q40612167-DE5533DA-E6E6-435E-AD26-F1BF7EC34F99Q41542027-3DCAFE05-01A0-4B25-9DFE-8501356A9F8AQ42213046-DDE5511C-A1DA-4E21-B172-B7F103BF51D9Q46397769-C5DD4D4B-F573-4E57-87D0-2378B54F65EBQ47306035-CF1714CE-ADBB-4931-A86D-AD7AD6FE56BDQ50014381-AFAC9A81-F198-43F3-AC4F-F8E198AB7024Q51285294-3915CA16-B736-4306-ABE7-F9D67F95A1D6Q53210224-169B6C7A-7E06-4213-A5B6-C62F9C9A0317Q54420274-070FCD4D-7EA3-46E4-9CB6-52739FC01BF2
P2860
Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@nl
type
label
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@en
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic and pharmacody ...... ymorphism in healthy subjects.
@en
P2093
P2860
P304
P356
10.1038/SJ.CLPT.6100324
P407
P577
2007-08-08T00:00:00Z